Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05394350 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT05394350 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 27 participants.
The verdict
NCT05394350, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional therapy. The effect of MK-1088 on tumor size will also be examined.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG MK-1088
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2023-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05394350
The ClinicalTrials.gov registry entry for NCT05394350 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05394350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05394350 about?
NCT05394350 is a clinical study titled "A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)". The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional therapy. The effect of MK-1088 on tumor size will also be examined.
What is the current status of trial NCT05394350?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2022-07-07. Estimated completion is 2023-09-07.
What interventions are being tested in trial NCT05394350?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-1088 (DRUG).
Who is sponsoring clinical trial NCT05394350?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.